key: cord-0788831-64cx1ohk
authors: Shinjyo, Noriko; Kagaya, Wataru; Pekna, Marcela
title: Interaction Between the Complement System and Infectious Agents – A Potential Mechanistic Link to Neurodegeneration and Dementia
date: 2021-08-02
journal: Front Cell Neurosci
DOI: 10.3389/fncel.2021.710390
sha: 4ab9db5f57fa29ef36d8e04060aee61c71803d28
doc_id: 788831
cord_uid: 64cx1ohk

As part of the innate immune system, complement plays a critical role in the elimination of pathogens and mobilization of cellular immune responses. In the central nervous system (CNS), many complement proteins are locally produced and regulate nervous system development and physiological processes such as neural plasticity. However, aberrant complement activation has been implicated in neurodegeneration, including Alzheimer’s disease. There is a growing list of pathogens that have been shown to interact with the complement system in the brain but the short- and long-term consequences of infection-induced complement activation for neuronal functioning are largely elusive. Available evidence suggests that the infection-induced complement activation could be protective or harmful, depending on the context. Here we summarize how various infectious agents, including bacteria (e.g., Streptococcus spp.), viruses (e.g., HIV and measles virus), fungi (e.g., Candida spp.), parasites (e.g., Toxoplasma gondii and Plasmodium spp.), and prion proteins activate and manipulate the complement system in the CNS. We also discuss the potential mechanisms by which the interaction between the infectious agents and the complement system can play a role in neurodegeneration and dementia.

The complement system is an evolutionarily conserved proteolytic cascade, consisting of over 40 components (Schartz and Tenner, 2020) . Complement plays a key role as part of the innate immunity, eliminating pathogens and damaged cells, directly killing bacteria by forming the so-called membrane attack complex (MAC), and promoting inflammatory responses via the generation of anaphylatoxins (Yanamadala and Friedlander, 2010) . The activation of the complement system can be triggered via three pathways: the classical pathway, the lectin pathway, and the alternative pathway (Veerhuis et al., 2011 ; Figure 1) .

Each of the activation pathways leads to the formation of C3 convertase (C4bC2b or C3bBb) that cleaves the third complement component (C3) into the C3a and C3b fragments, the latter of which functions as an opsonin, forms the C3 convertase of the alternative pathway (C3bBb) and takes part in the next step of the activation cascade, i.e., proteolytic cleavage of C5. C5 activation results in the release of C5a and the formation of MAC, a.k.a. the terminal complement complex, C5b-9. C3a and C5a are peptides with anaphylatoxin properties and function as fluid-phase inflammatory mediators. They exert their biological effects mainly through the cognate membrane-bound receptors C3a receptor (C3aR) and C5a receptor (C5aR1), respectively. C5a can also bind to the second C5a-like receptor (C5L2, C5aR2). C5aR1 can propagate proinflammatory signals to induce cytokine/chemokine release and mediate the chemoattraction and activation of neutrophils and macrophages (Mathern and Heeger, 2015) . C3aR signaling is immunomodulatory, exerting pro-or anti-inflammatory effects in a context-dependent manner (Coulthard and Woodruff, 2015) . For example, C3aR activation enhances phagocytosis by macrophages (Wu et al., 2019) and suppresses injury-induced mobilization of neutrophils (Wu et al., 2013; Brennan et al., 2019) . Besides its C3aR-mediated actions, C3a has a direct anti-microbial activity (Pasupuleti et al., 2007) , indicating its multiple modes of action as an anti-infective agent. Even without antibodies, complement can neutralize pathogens (Speth et al., 2002) . In addition, there are links between complement and adaptive immunity, such as the robust augmentation of antibody responses mediated by the C3d fragment (proteolytically generated from C3b) and complement receptor 2 (CR2) (Dempsey et al., 1996) and the regulation of T cell activation by C3a/C5a (Lalli et al., 2008) . Thus, the complement system has crucial functions in both innate and adaptive immune responses (Mathern and Heeger, 2015) . In addition, recent reports show that a number of cell types store intracellular C3 (Elvington et al., 2016) , which has been proposed to have an important role in the regulation of cellular homeostasis (Liszewski et al., 2017) . For example, cathepsin L-mediated intracellular C3 cleavage and C3a generation are required for homeostatic T cell survival (Liszewski et al., 2013) . Airway epithelial cells can de novo synthesize C3, and intracellular C3 protects these cells from stress-induced cell death (Kulkarni et al., 2019) . Intracellular C3 is also required for autophagic turnover of pancreatic β cells during diabetic stress (King et al., 2019) . Notably, C3 is an evolutionarily ancient protein; it is considered to be the first element of the original complement system, whose primary role was to guard intracellular environment and homeostasis from various stimuli (Elvington et al., 2016) . While complement is widely acknowledged as part of vertebrate humoral immunity, the significance of intracellular complement is less recognized. The potential role for intracellular C3 in self-defense against infection warrants further investigation.

The classical pathway is initiated by binding of C1 (C1qrs) to activators such as immune complexes, microbes, apoptotic cells, and some specific proteins including fibrillar amyloid β (Aβ) (Veerhuis et al., 2011) . The lectin pathway is activated by binding of mannose-binding lectin (MBL) and ficolin to carbohydrates on microorganisms or dying cells (Veerhuis et al., 2011) . The classical and lectin pathways converge at the proteolytic cleavage of C4 and C2 and the formation of C4bC2b, the C3 convertase shared by these pathways. The alternative pathway continuously generates low levels of C3-derived activation products and C3 convertase C3bBb, providing a natural immunity to microbes (Farriesa and Atkinson, 1991) . The activation of alternative pathway can also occur as a result of direct interaction between C3b and pathogenic molecules, including fibrillar Aβ, further amplifying the downstream of complement cascade (Tenner, 2020) . C3 and C5 can be cleaved also by MASP 1 (Matsushita and Fujita, 1995) , neutrophil elastase (Yuan et al., 2015) , cathepsins (Liszewski et al., 2013; Yuan et al., 2015) , granulocyte proteases (Johnson et al., 1976) , lysosomal enzymes, kallikrein, coagulation factors XIa, Xa, IXa, thrombin, and plasmin (Markiewski and Lambris, 2007; Amara et al., 2010) . This non-convertase mode of activation is also called the extrinsic pathway.

Under physiological conditions, complement activity is tightly regulated by regulators of complement activation (RCA) to safeguard against autologous tissue injury. The RCAs that limit complement activation both in time and space include factor H (FH), factor I, C1-inhibitor, C4-binding protein, clusterin, vitronectin, CD46 (membrane cofactor protein, MCP), CD55 (decay accelerating factor, DAF), and complement receptor 1 (CR1, CD35). Properdin (FP), on the other hand, acts as a positive regulator that stabilizes the alternative pathway C3convertase (Figure 1 ).

Although the liver is the major source of circulating soluble complement proteins (Perlmutter and Colten, 1986) , it is now established that complement components are locally synthesized throughout the body, including the brain (Woodruff et al., 2010; Tenner et al., 2018) . Complement proteins, including the regulatory factors and receptors, are produced by glia and neurons Ischenko et al., 1998; Nataf et al., 1999) , and recent studies have revealed a range of nonimmune functions of the complement system in the CNS. For example, complement deposition on synapses, followed by CR3-dependent microglial engulfment and elimination of C1qand C3b/iC3b-tagged synapses, plays a crucial role in synaptic pruning during normal development (Schafer et al., 2012) . C3aR and C5aR are expressed by neurons and glia in the brain under normal and pathological conditions (Barnum et al., 2002) . C3aR signaling regulates neuronal migration during CNS development (Gorelik et al., 2017) , controls neural progenitor cell proliferation (Coulthard et al., 2018) , differentiation and migration in vitro (Shinjyo et al., 2009) , and promotes basal as well as injuryinduced neurogenesis in the adult mouse brain (Rahpeymai et al., 2006; Shinjyo et al., 2009; Stokowska and Pekna, 2018) . Notably, mice lacking C3 exhibit excessive number of synapses as young adults (Stevens et al., 2007; Perez-Alcazar et al., 2014) and neuronal migration defects characteristic of autism spectrum disorder (Gorelik et al., 2017) , and are protected against agerelated loss of synapses in the hippocampus (Shi et al., 2015) . Higher expression of C4 in the brain has been implicated in excessive loss of synapses and development of schizophrenia (Sekar et al., 2016) . C3aR deficiency is associated with altered morphology of the hippocampus and amygdala, mild cognitive impairment and hyperactive behavior in unchallenged mice (Coulthard et al., 2018; Pozo-Rodrigálvarez et al., 2021) as well FIGURE 1 | The complement system: activation pathways and functions in the CNS. All three pathways converge at C3. The formation of C3 convertase [C3(H 2 O)Bb and C3bBb in the alternative pathway or C4b2b in the classical and lectin pathways], followed by C3 cleavage, leads to the formation of MAC, the terminal complement complex (A). C1q and iC3b also facilitate immune responses via opsonization and promoting phagocytosis through binding to the receptors (CR1 and C1qR for C1q; CR1, CR2, and CR3 for iC3b) (B). Under physiological conditions, complement activation is tightly controlled by the regulators of complement activation (RCAs) (C). C3a and C5a, the smaller fragments generated through the proteolytic activation of C3 and C5, respectively, regulate differentiation and mobilization of immune and non-immune cells through the cognate receptors C3aR and C5aR, respectively (D). C3 and C5 can be also cleaved by other proteases via the so-called extrinsic pathway. C1qR, C1q receptor; C3bBb3b, C5 convertase formed by binding of additional C3b to C3bBb (C3 convertase); C3(H 2 O), hydrated C3; C3(H 2 O)Bb, the initiating C3 convertase of alternative pathway, consisting of C3(H 2 O) and Bb (Factor B [FB] cleavage product); CR1, complement receptor type 1; CR2, complement receptor type 2; CR3, complement receptor type 3; CR4, complement receptor type 4; FH, complement factor H; FI, complement factor I. C4BP, C4-binding protein; C1INH, C1-inhibitor.

as reduced neural plasticity responses after ischemic brain injury (Stokowska et al., 2017) . Thus, the complement system is required for the normal development and function of the CNS.

Considering the broad range of neurodevelopmental and neuroregulatory functions of complement in the brain, it is not surprising that dysfunction or aberrant activation of the complement system have been implicated in the pathogenesis of a number of brain disorders (Gasque et al., 2000; Morgan, 2015) . More specifically, complement activation has been observed in human neurodegenerative diseases, such as Alzheimer's disease (AD), prion disease, chromosome 13 dementias (Eikelenboom et al., 2002; Rostagno et al., 2002; Morgan, 2018) , as well as other neurological disorders associated with the blood-brain barrier (BBB) dysfunctions such as cerebrovascular disease, multiple sclerosis (MS) (Storch et al., 1998) , and meningitis (Koelman et al., 2019) . In infection, while providing protection against pathogens, excessive or prolonged activation of the complement system can lead to exaggerated inflammation and unfavorable outcomes (Ross and Densen, 1984 ; Figure 1 ).

Dementia is a broad term for conditions with progressive memory impairment, executive and behavioral anomaly, and emotional problems, affecting the ability to perform day-to-day activities. Complement activation is implicated in AD, the most prevalent form of dementia (Rubio-Perez and Morillas-Ruiz, 2012) . Together with glial activation and pro-inflammatory cytokine release, complement activation occurs during the early stage of the disease progression (Aiyaz et al., 2012) . As described above, amyloid proteins stimulate complement activity (Veerhuis et al., 2011; Tenner, 2020) , leading to the activation of the surrounding glial cells and local chronic inflammation (Cadman and Puttfarcken, 1997; Veerhuis et al., 2011) . Complement proteins are present in amyloid plaques in the brain (Aiyaz et al., 2012) , and co-localize with Aβ in the brain capillaries of cerebral amyloid angiopathy (Matsuo et al., 2017) , suggesting that complement activation is a key event associated with amyloid deposition. In addition, complement is likely involved in other forms of dementia, including chromosome 13 dementias (familial British dementia FBD and familial Danish dementia FDD). Similar to AD, chromosome 13 dementias are associated with neurodegeneration and amyloid deposition in the CNS. In spite of the structural differences in the disease-associated amyloid proteins (Aβ in AD, ABri in FBD, ADan in FDD), neurodegeneration and amyloid deposition, associated with glial activation and local inflammation, are the common hallmark in all of these dementias (Saul et al., 2013) . Importantly, complement activation products co-localize with amyloid plaques and related deposits in FBD and FDD (Rostagno et al., 2002) . ABri and ADan synthetic peptides activate classical and alternative complement pathways, leading to the formation of the terminal complex (C5b-9). These data suggest that chronic complement activation associated with amyloid deposits may be a contributing factor to dementia progression in chromosome 13 dementias as well as in AD. While experimental evidence points to the critical function of complement in Aβ clearance (Wyss-Coray et al., 2002) , and C3-and CR3-dependent microglial phagocytosis appears to play a beneficial role in the elimination of foreign pathogens as well as Aβ (Fu et al., 2012) , CR3 also limits Aβ clearance from the brain interstitial fluid (Czirr et al., 2017) , and is involved in Aβ-induced microglia-mediated loss of synapses in AD (Hong et al., 2016) . The complexity of the involvement of complement in AD type of neurodegeneration is further highlighted by findings in the C3 deficient mice carrying the AD-associated mutations in the amyloid polypeptide and presenilin 1 genes. In this model, the C3 deficiency was protective against plaque-related synapse and neuron loss as well as cognitive decline, despite higher plaque burden (Shi et al., 2017) . In addition, C1q and CR3 are required for the clearance of neuronal debris by microglia, at least in the context of injury-induced neurodegeneration (Norris et al., 2018) . By virtue of its proinflammatory functions, C5a plays a significant role in neurodegeneration, including AD (Landlinger et al., 2015) . Jointly, these reports point to the role of the complement system in Aβ and debris clearance as well as synapse elimination, Aβinduced neurodegeneration and dementia.

In the presence of an intact BBB, circulating immune cells, such as B-and T-lymphocytes, have limited access to the CNS. As a result, the defense of brain tissue against invading pathogens is largely dependent on local innate immunity, in particular the complement system. A number of pathogens escape the peripheral immune responses and enter the CNS. The interaction between pathogens and complement can lead to the clearance of pathogens, however, it may also contribute to tissue damage. Here we summarize the interactions between complement and infectious organisms, including bacteria, viruses, fungi, and parasites (Table 1) , and discuss the potential impact of these interactions on CNS function. The interactions between complement and prion proteins are also discussed.

Genetic defects in the complement system increase the susceptibility to bacterial infection (Brouwer et al., 2009 ). C2, factor D (FD), and FP deficiencies are associated with predisposition to meningococcal disease (Fijen et al., 1999; Jönsson et al., 2005; Sprong et al., 2006) , while singlenucleotide polymorphisms (SNPs) in MBL are associated with pneumococcal disease (Brouwer et al., 2009) . FH genotype 496C/C is associated with meningococcal disease (Haralambous et al., 2006) as is a locus in the FH (CFH) region (Davila et al., 2010) . C3a exhibits anti-microbial activity against Gram-negative and Gram-positive bacteria (Pasupuleti et al., 2007) . These data show that complement-dependent immune response is crucial in the protection against bacterial infection.

The evidence for the involvement of the complement system in bacterial meningitis is summarized in Table 1 .1. Bacterial meningitis is an acute inflammation caused by infection in the meninges that envelope and protect the brain and spinal cord. Commonly caused by Streptococcus pneumoniae, Neisseria meningitidis, and Listeria monocytogenes, bacterial meningitis is a major health threat, the morbidity and mortality of which are driven by dysregulated host immune reactions (Mook-Kanamori et al., 2011; van de Beek et al., 2016) .

As the long-term sequelae of bacterial meningitis include cognitive impairment, infection-induced inflammation may have lasting or even permanent impact on brain function (van de Beek et al., 2004) , and there is strong experimental and clinical evidence for the detrimental role of complement in meningitis. Inhibition of the classical pathway and of C5 were both protective against meningitis caused by S. pneumoniae in rodents (Zwijnenburg et al., 2007; Woehrl et al., 2011) , and a single nucleotide polymorphism of C5 (rs17611, encoding V802I) was associated with poor outcome in pneumococcal meningitis patients (Woehrl et al., 2011) , indicating that the activation of the classical complement pathway plays a key role in the pathogenesis. In murine bacterial meningitis model, L. monocytogenes infection caused the up-regulation of C3 and FB mRNA levels in the cerebrospinal fluid (CSF) as well as in parenchymal neurons (Stahel et al., 1997) , implicating local activation of the alternative pathway in the brain during meningitis. C3aR is up-regulated in glial cells and infiltrating immune cell populations in the brain tissue autopsy from bacterial meningitis patients , and C5aR deficient mice were less susceptible to meningitis development despite unaltered bacterial titers in the brain (Woehrl et al., 2011) , suggesting the important roles for anaphylatoxin receptor signaling in infection-induced neuroinflammation.

FH and CD46, the negative regulators of the complement system, contribute to or even enable of bacterial dissemination into the CNS. FH binding protein (Fhb) is a meningococcal protein that binds to human FH. The interaction between Fhb and host FH enables the bacteria to evade the innate immune attack, thereby facilitating systemic dissemination. Streptococcus suis, a zoonotic bacterium causing bacterial meningitis (Dominguez-Punaro et al., 2007) , expresses Fhb, which contributes to the S. suis virulence via inhibition of C3b/iC3b deposition on the bacterial surface (Pian et al., 2012) . In addition, Fhb can contribute to the development of severe meningitis by enhancing the traversal of S. suis across the BBB, as suggested by in vivo and in vitro experiments (Kong et al., 2017) . Similarly, CD46 acts as the entry receptor for a number of microbes, including N. meningitidis, an exclusively human pathogen. While CD46 is ubiquitously expressed in human tissues, it is only expressed in the eye and spermatozoa in mouse (1) S. epidermidis inoculation caused sepsis and blood CSF barrier disruption in preterm pigs.

(2) Acute-phase immune response proteins, including complement proteins (C1r, C3, and C5), were up-regulated in CSF at 24 h post-infection. (2) Gb3 deficiency was protective against meningitis.

Fhb facilitates BBB invasion and traversal. Kong et al., 2017 3

Pneumococcal meningitis (1) (Human) nationwide prospective cohort study of adults with community-acquired bacterial meningitis (n636) vs. control (partners or non-related proxies living in the same dwelling).

(2) (in vivo) C5aR deficient mice. (1) Intrathecal treatment with C1-inh reduced clinical symptoms and inflammatory infiltrate/leukocyte influx.

(2) C1-inh treatment induced CR3 expression in the brain. Human CD46 transgenic mice showed:

(1) delayed bacterial clearance from blood and increased serum cytokines (TNF, IL-6, and IL-10).

(2) microglial and astroglial activation in the brain.

(3) Host immune responses were absent when LPS-deficient meningococci were used.

CD46 is crucial in the pathogenesis of meningitis. (1) N. meningitidis crossed BBB in CD46 transgenic but not WT mice.

(2) CD46 transgenic mice had 100% mortality, while 100% of WT mice survived.

Human CD46 facilitates bacterial translocation across BBB. Johansson et al., 2003 7 Meningitis-causing bacteria (Human) Brain tissue autopsy from bacterial meningitis patients

C3aR was upregulated and expressed by reactive astrocytes, microglia, and infiltrating macrophages and neutrophils.

C3aR is upregulated in glial cells and infiltrating immune cells in the brain. Gasque et al., 1998 8 Listeria monocytogenes (in vivo) Bacterial meningitis model, mice infected with Listeria monocytogenes.

C3 and FB mRNA levels were elevated in CSF, neurons and Purkinje cells.

Alternative complement pathway (C3 and FB) is activated in the brain. Stahel et al., 1997 The relevant complement proteins are highlighted in bold.

Frontiers in Cellular Neuroscience | www.frontiersin.org (Liszewski et al., 2000; Lyzogubov et al., 2014) . N. meningitidis does not enter the brain in wild-type mice. However, in genetically engineered mice that express human CD46 (human CD46 transgenic), N. meningitidis traversed BBB, leading to significantly higher mortality (Johansson et al., 2003) . In addition to delayed bacterial clearance from the circulation, microglial and astroglial activation was observed in the brain of CD46 transgenic mice (Johansson et al., 2005) . These data suggest that N. meningitidis utilizes CD46 to facilitate its own entry into the CNS. Systemic infection and sepsis can sensitize the brain to inflammation via complement activation, even without the bacteria entering the CNS. In preterm infants, S. epidermidis triggers cerebral inflammation, white matter injury and impaired neurodevelopment (Bi et al., 2015) . While Toll-like receptor 2 (TLR2) is thought to be the major contributor to neonatal infection caused by Gram-positive bacteria, the observation that the CSF levels of C1r, C3, and C5 were rapidly increased in S. epidermidis infection-induced sepsis model in pigs (Muk et al., 2019) suggests that systemic infection may cause CNS injury via aberrant activation of the complement cascade. Bacterial lipopolysaccharide-induced long-term depression via microglial CR3 activation offers a specific mechanistic link between neuroinflammation, complement activation, synaptic dysfunction, and memory impairments .

While complement protects the host against bacterial infection, excessive complement activation can contribute to CNS injury and long lasting or permanent dysfunction. In addition, several complement components and regulators are exploited by bacteria to facilitate their entry into the CNS.

A large number of brain disease-causing viruses, including herpes viruses (human herpes virus 1 [HSV-1], human herpesvirus 6 [HHV-6], and γ-herpesviruses), HIV, measles virus, Borna disease virus (BDV), Theiler's murine encephalitis virus (TMEV), Venezuelan equine encephalitis virus (VEEV), West Nile virus (WNV), and Zika virus (ZIKV), interact with the complement system in the CNS (Table 1. 2) and this interaction may play a role in neurodegeneration. Latent HSV-1 infection is associated with increased risk for AD (Itzhaki, 2018) . HHV-6A and HHV-6B are frequently found in patients with neuroinflammatory diseases including MS (Alvarez-Lafuente et al., 2006) and AD (Readhead et al., 2018) . γ-herpesviruses, including human Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), also establish life-long latency in the host, which is associated with increased risk of diverse neurological conditions, including meningitis, encephalitis, HIV-related CNS lymphoma, and MS (Said et al., 1997; Bossolasco et al., 2006; Serafini et al., 2007) . Seropositivity for EBV is associated with clinical AD (Carbone et al., 2014) . In HIV patients, KSHV infection can manifest in the CNS (Andrews et al., 2011; Baldini et al., 2013; Tso et al., 2017) . In addition, HIV can cause cognitive impairment, so called HIV-associated neurocognitive disorders (HAND, NeuroAIDS). Indeed, while antiretroviral therapy effectively inhibits viral replication and reduces mortality, more than 50% of HIV-positive individuals suffer from cognitive impairment (Clifford, 2017; Olivier et al., 2018) . Even though antiretroviral therapy suppresses viral replication, neurotoxic HIV proteins, such as Tat, continue to be produced in the CNS, leading to persistent inflammation (Liu et al., 2014; Avalos et al., 2017) . WNV is a neuroinvasive pathogen that causes significant neuronal loss, inflammation, and microglial activation (Clarke et al., 2014) . WNV targets hippocampal neurons (Armah et al., 2007) , and patients recovering from WNV disease often suffer from cognitive impairment (Sejvar et al., 2003; Sadek et al., 2010) . ZIKV is the causative agent of Zika fever, congenital infection which leads to severe developmental neurodevelopmental defects, including neonatal microcephaly (Rasmussen et al., 2016; Russo et al., 2017) . The fact that ZIKV infection in adults can lead to neurological complications such as acute myelitis, encephalomyelitis, encephalitis, meningoencephalitis, and sensory polyneuropathy (Mécharles et al., 2016; Brito Ferreira et al., 2017) , further strengthens the notion that ZIKV is highly neurotropic . VEEV is endemic to Central and South America and periodically emerges from the enzootic cycle to cause infection in human and equid populations (Weaver and Barrett, 2004) , occasionally causing severe encephalomyelitis . Measles virus infects over 40 million individuals per year (McChesney and Oldstone, 1989) . Acute infection can cause encephalomyelitis, the neurological sequelae of which include subacute sclerosing panencephalitis (SSPE) and measles inclusion body encephalitis (MIBE) (Griffin, 2020 ).

The complement system provides the first line of defense against viruses, including HSV-1 via the lectin pathway (Bibert et al., 2019) , and γ-herpesvirus, VEEV, and WNV via C3-dependent elimination mechanisms (Kapadia et al., 2002; Mehlhop et al., 2005; Brooke et al., 2012) . On the other hand, the virus-induced up-regulation of complement components in the CNS may lead to BBB dysfunction and contribute to tissue damage in infection with HIV and TMEV (Speth et al., 2004; Woollard et al., 2014; Libbey et al., 2017) . For example, HIV-Tat protein upregulated C3 expression in human brain microvascular endothelial cells (HBMEC) in vitro (Woollard et al., 2014) , C1q is upregulated in the brain of Simian immunodeficiency virus (SIV)-infected rhesus macaques (Speth et al., 2004; Depboylu et al., 2005) and mice after HIV-Tat injection into the cerebral cortex (Hammond et al., 2018) , two in vivo models of NeuroAIDS. Increased C1q in the CSF is associated with cognitive impairment in HIV-infected individuals (McGuire et al., 2016) . BDV induced local C1q mRNA expression in the hippocampus and cortex (Dietzschold et al., 1995) and ZIKV infection enhanced expression of C1q and C3, associated with microglial activation and hippocampal synaptic damage and memory impairment in a murine infection model using ZIKV intracerebroventricular infusion . In murine model induced by intracranial infection of WNV, C1q protein colocalized with microglia adjacent to WNV-infected neurons, possibly causing synaptic terminal loss (Vasek et al., 2016) . These data suggest that local complement activation may induce cognitive impairment via the disruption of neurotransmission. (1) C1q mRNA was upregulated in the brain of BDV-infected rats.

(2) C1q positive cells (presumably microglia) were preferentially localized in the hippocampus and basolateral cortex.

Local C1q expression is induced in the brain after BDV infection.

Herpes viruses 1 HSV-1 (1) (Human, clinical case report) Herpes simplex virus encephalitis (HSE) in patients.

(2) (in vivo) HSV-1 infection-induced HSE in MBL-deficient mice.

(1) HSE patients had MASP2 heterozygous mutation (G634R and R203W) without defect in TLR3-interferon signaling pathway. Both MASP2 variants induced functional defects in MASP-2 and reduced antiviral activity.

(2) MBL deficient mice showed a decreased survival rate and increased HSV-1 burden in the brain.

The lectin pathway (MASP-2 and MBL) is involved in the anti-HSV activity. Defect in the lectin pathway can lead to higher susceptibility to adult HSE. (1) C3b induced MSRV-Env expression.

(2) Antibodies recognizing SCR3 and/or SCR4 of CD46 triggered MSRV transactivation.

(3) Knockdown of CD46-Cyt1 isoform led to loss of HHV-6A-induced MSRV-Env expression.

The engagement of CD46-SCR3 and/or CD46-SCR4, either by HHV-6A or C3b, induces MSRV-Env. HHV-6A-induced MSRV-Env can activate TLR4 signaling. (Charvet et al., 2018) 3 HSV-1 (in vitro) HSV-1 brain infection model using human primary neural cells (neurons + glia).

(1) HSV-1 infection in neural cells caused atrophy and irregular morphology.

(2) Infection induced the up-regulation of miRNA-146a and pro-inflammatory mediators, while reducing FH protein (known as a miRNA-146a target) levels. (1) Human oligodendrocytes, astrocytes and microglia express CD46.

(2) CD46 inhibition (anti-CD46 antibody) suppressed the fusion of HHV-6-infected T cells with glial targets (oligodendrocytes and astrocytes).

HHV-6 may spread into the CNS via cell-cell fusion of infected lymphocytes and glial cells, which is mediated by CD46 on the surface of glia. (1) gHV68-RCA deficient virus exhibited lower infection efficiency in the brain and periphery (lung and spleen) in acute and chronic infection.

(2) C3 deficient caused higher susceptibility to viral latency in the CNS.

(3) Lower infection efficiency of gHV68-RCA deficient virus compared to WT virus was absent in C3 deficient mice (but not in FB deficient mice). (1) C1q and C3 were upregulated around injection site and corpus callosum in HAND model (Tat-injected).

(2) Iba1 + microglia increase and synaptic loss were induced in HAND model.

(3) C1q deficient did not prevent Tat-induced synaptic loss and microgliosis. (1) CSF C1q correlated with NFL in subjects without antiretroviral therapy.

(2) A trend towards (p = 0.052) elevation of CSF C1q expression in subjects with cognitive impairment compared to those with normal cognition.

Increased C1q in CSF, which is associated with cognitive impairment.

(Continued)

Frontiers in Cellular Neuroscience | www.frontiersin.org HIV-1 Tat proteins increased the expression of C3 and C3b in HBMEC. Heat inactivated Tat proteins (Tat.B-HI and Tat.AG-HI) also upregulated C3 and C3b.

HIV Tat protein upregulates C3 and C3b in HBMEC, which may cause BBB dysfunction. (Woollard et al., 2014) 4 (in vivo) Neuro-AIDS model using SIV-infected rhesus macaques

(1) C1q protein and transcripts colocalized with microglial/macrophage lineage in SIV-encephalitic brains. All SIV-positive cells were also C1q-positive.

(2) CNS-permeant antiretroviral agent decreased C1q synthesis, SIV burden, and inflammation in AIDS-symptomatic macaques.

Classical complement pathway activation. Depboylu et al., 2005 5 (in vivo) Neuro-AIDS model using SIV-infected rhesus macaques. Measures: IHC

(1) C1q and C3 levels increased in astrocytes, microglia, and neurons of SIV-infected macaques compared to control.

(2) Infiltrating macrophages and multinuclear cells in the brain also expressed C1q and C3 in infected animals.

(3) C1q and C3 were deposited on the membrane of neurons. 1. Strong CD46 signal was observed on cerebral endothelium throughout the brain as well as on ependymal cells lining the ventricles and choroid plexus, while subsets of neurons and oligodendrocytes were also weakly CD46 positive.

2. In SSPE brain, cells in MV-infected lesions were negative for CD46.

(1) CD46 is present on endothelial, neuronal, and glial cells in the CNS.

(2) MV infection may down-regulate CD46 in SSPE brain. (1) VEEV infection via peripheral route caused more severe symptom and enhanced invasion and inflammation in the brain of C3 deficient mice compared to WT.

(2) Direct inoculation of VEEV into the brain led to identical outcomes irrespective of the presence or absence of C3.

C3-dependent viral clearance in the periphery is critical for the protection against VEEV-induced encephalitis.

West Nile virus (WNV)

Mouse strains: WT, C3 deficient and C3aR deficient

(1) WNV infection causes synaptic loss in the hippocampal CA3 region.

(2) WNV-recovered mice exhibited cognitive deficits without impairment in motor activity.

(3) C1qa protein colocalized with microglial processes adjacent to neurons. C3d colocalized with synaptic terminals.

(4) C3 deficient and C3aR deficient mice were protected against WNV-induced synaptic loss. (1) WNV was detected earlier and in greater levels in the brain and spinal cord of C3 deficient and CR1/CR2 deficient mice, compared to WT.

(2) High levels of WNV antigen were detected primarily in neurons. In WT mice, WNV positive neurons were detected in the cortex, hippocampus, and brain base. Significantly enhanced and more widespread WNV signals were observed throughout the brain in C3 deficient compared to WT mice.

(3) The development of WNV-specific antibodies was blunted in C3 deficient and CR1/CR2 deficient mice. C3 deficient and CR1/CR2 deficient mice had higher mortality after exposure to a low dose WNV.

C3 and CR1/CR2 play a key role in antibody-mediated protection against WNV, thereby reducing the risk of viral dissemination into the brain.

Complement receptor 1 (CR1): C3b/C4b receptor, CD35.

Complement receptor 2 (CR2): complement C3d receptor, Epstein-Barr virus receptor, CD21.

Study design Outcomes Conclusion References

(2) (Human, ex vivo) ZIKV infection in human adult cortical tissue ex vivo.

(1.1) ZIKV infected mature neurons in the frontal cortex and hippocampus in mice.

(1.2) Infection caused microgliosis, the elevation of TNF-a, and upregulation of complement proteins (C1q and C3).

(1.3) Infection caused hippocampal synaptic damage and memory impairment.

(2) ZIKV infected mature neurons and replicated in adult human brain tissue.

(a) ZIKV infects neurons in the hippocampus and frontal cortex (b) ZIKV infection causes upregulation of complement proteins (C1q and C3), which is associated with microglial activation and pro-inflammatory response.

The relevant complement proteins are highlighted in bold.

Frontiers in Cellular Neuroscience | www.frontiersin.org Some viruses increase their virulence by manipulating complement regulatory proteins. HSV-1 infection caused the down-regulation of FH in human primary neuroglia in vitro (Hill et al., 2009) , potentially leading to enhanced activity of the alternative pathway. As suggested by studies using CD46 transgenic mice, CD46 is involved in the dissemination of measles virus into the CNS, increasing the risk of measles encephalitis (Rall et al., 1997; Manchester et al., 1999; Oldstone et al., 1999; Evlashev et al., 2000) . In postmortem SSPE brain tissues, strong CD46 signal was observed on cerebral endothelium throughout the brain, as well as ependymal cells lining the ventricles and choroid plexus (McQuaid and Cosby, 2002) , while CD46 expression was suppressed by measles virus infection in SSPE lesions (Ogata et al., 1997; McQuaid and Cosby, 2002) . In addition, CD46 expression was observed in primary human glial cells (oligodendrocytes, astrocytes, and microglia) and CD46 inhibition by anti-CD46 antibody suppressed the fusion of glia and measles virus-infected T cells in vitro, suggesting that measles virus may spread in the brain parenchyma via binding to CD46 on glia (Cassiani-Ingoni et al., 2005) . In HHV-6 infection models in vitro, using neuronal and glial cell lines, CD46 also mediated HHV-6 infection-induced transactivation of Multiple Sclerosis-Associated Retrovirus (MSRV) (Charvet et al., 2018) . In a murine γ-herpesviruses infection model, C3 deficiency caused higher susceptibility to viral latency in the CNS (Kapadia et al., 2002) . Several γ-herpesviruses encode homologues of RCAs (Farriesa and Atkinson, 1991) , to inhibit complement activation (Fodor et al., 1995; Kapadia et al., 1999 Kapadia et al., , 2002 thereby preventing complement-mediated elimination (Liszewski et al., 1996; Russo et al., 1996; Virgin et al., 1997) . Like bacteria, some viruses can utilize and mimic host RCA proteins for their dissemination and entry into the CNS.

Sustained complement activation is associated with neuroinflammation and neurodegeneration in a number of neurological disorders (Eikelenboom et al., 1989; Rogers et al., 1992) . Of note, COVID-19 patients reportedly suffer from diverse neurological complications (Stracciari et al., 2021) . Although there is no direct evidence thus far to indicate causality between SARS-CoV-2 infection and neuropathology (Maury et al., 2021) , future research will show whether there is a causal link between overactivation of complement in response to SARS-CoV-2 and neurological symptoms or long-term complications of COVID-19 (Garred et al., 2021) .

Fungal infection and dissemination into the brain has been proposed to contribute to the etiology of AD (Alonso et al., 2014 (Alonso et al., , 2018 . Candida is one of the most common commensal fungi, and can cause systemic infections which frequently affect the CNS (Lionakis et al., 2011; Alonso et al., 2014 Alonso et al., , 2018 . Mice with invasive candidiasis exhibit microglial activation and local inflammation (Lionakis et al., 2011) . Aspergillus and Cryptococcus are also fungal species that can cause invasive CNS infection, especially in immunocompromised individuals (Panackal and Williamson, 2015) . Similarly, cerebral aspergillosis is caused by Aspergillus spp. that mainly affect immunocompromised individuals, such as AIDS patients and those under immunosuppressive treatment regimens (Ruhnke et al., 2007) . Cryptococcosis, caused by the encapsulated fungus Cryptococcus neoformans, frequently occurs in AIDS, organ transplant recipients and cancer patients, and is the leading cause of mortality in immunocompromised individuals (Rajasingham et al., 2017) . These fungal species can also cause meningoencephalitis (Gottfredsson and Perfect, 2000; Góralska et al., 2018) , suggesting that fungal infection-induced local inflammation and meningoencephalitis may lead to long-term sequelae including cognitive dysfunction.

The complement system plays pivotal roles in the susceptibility to fungal CNS infection and infection-induced neuropathology (Table 1.3) . A study using murine Candida albican infection models showed that C5 could be a major determinant of CNS infection susceptibility (Tuite et al., 2005) . Neutrophils play a major protective role against dissemination of C. neoformans (Lovchik and Lipscomb, 1993; Graybill et al., 1997) , and C5aR signaling is required for infection-induced neutrophil recruitment to the brain as suggested by data obtained in a murine infection model using C5 deficiency and inhibitory anti-C5aR antibodies . C5 and its cleavage product C5a are required for pulmonary accumulation of neutrophils upon infection and intravascular clearance of C. neoformans (Lovchik and Lipscomb, 1993; Sun et al., 2016) , further confirming the crucial roles for C5 and C5a in neutrophilmediated killing of C. neoformans. Jointly, these data suggest that complement activation and C5aR signaling are protective against C. neoformans-induced meningoencephalitis. In postmortem brain tissues from subjects with cerebral aspergillosis, C1q, C4, C3, and C5 were up-regulated in the brain, and co-localized with neurons, astrocytes, oligodendrocytes, and infiltrating macrophages (Rambach et al., 2008) .

While the specific mechanistic links between fungal infection and dementia remain to be elucidated (Alonso et al., 2014 (Alonso et al., , 2018 , complement may be protective against neurodegenerative disorders via limiting fungal invasion into the CNS.

Protozoan parasites including Toxoplasma gondii and Plasmodium spp. are obligate intracellular organisms that can potentially cause dysfunction and parenchymal injury in the brain. While T. gondii infects all nucleated cells of warm-blooded vertebrates, erythrocytes are the main target in Plasmodium infection in vertebrates. Host immune responses to these eukaryotes are very complex (Ivanova et al., 2019) . The interactions between the complement system and these protozoa, with relevance for brain pathologies and the potential links to dementia, are summarized in Table 1 .4.

Plasmodium spp. are the agents causing malaria, one of the deadliest infectious diseases worldwide. Cerebral malaria (CM), caused by P. falciparum, is the most severe and life-threatening condition characterized by diffuse encephalopathy. CM is frequently accompanied by seizures and coma, and accounts for the majority of childhood deaths from malaria in endemic regions (Schmutzhard and Gerstenbrand, 1984; Idro et al., 2010;  (n2), acute myeloid leukemia (n2), aplastic anemia (n1), organ transplantation (n1). Compared to non-infected control (n7).

(1) C1q, C4, C3, and C5 were upregulated in the from Aspergillus-infected brain. C1q, C4, C3, and C5 were colocalized with neurons, astrocytes, oligodendrocytes, and infiltrating macrophages.

(2) High complement levels in the surrounding fibrous layer, but not in the central necrotic area loaded with fungal hyphae.

Complement synthesis increased in astrocytes, neurons, oligodendrocytes, and infiltrating macrophages in the surrounding fibrous layer.

Candida spp.

Murine model of Candida albicans infection. Genetic susceptibility was assessed by intercrossing two inbred strains: A/J (C5 deficient) and C57BL/6J (B6)

(1) Fungal load in the brain, kidney, and heart was significantly different between the two inbred strains: A/J was more susceptible compared to B6.

(2) C5 was a strong determinant for the brain and kidney susceptibility to infection.

C5 is a major gene responsible for genetic susceptibility to candidiasis.

Cryptococcus 1 (in vivo) Cryptococcus neoformans infection model in mice (WT, C3 deficient, and C5 deficient).

(1) C3 deficiency, C5 deficiency, and C5aR blockade (specific anti-C5aR mAb) reduced the intravascular clearance of C. neoformans.

(2) Upon infection, neutrophils recruitment to the lung and the brain was less efficient in C3 deficient and C5 deficient mice compared to WT. Neutrophil recruitment was also inhibited in WT mice treated with anti-C5aR.

(3) C5aR deficient neutrophils failed to be recruited to the infected lung.

(4) Intravascular clearance of disseminating C. neoformans is less efficient in the brain compared to the lung.

(5) LPS-treatment significantly enhanced neutrophil recruitment to the brain and C. neoformans clearance.

(a) Neutrophil recruitment is essential for intravascular clearance of C. neoformans.

(b) C5aR-dependent neutrophil recruitment is crucial for intravascular clearance of C. neoformans.

The relevant complement proteins are highlighted in bold. Riggle et al., 2020) . In addition, more than 10% of children who survive CM have persistent neurological sequelae, including those affecting cognition and behavior (Frevert and Nacer, 2014 (Grau et al., 2003; Francischetti, 2008; Bridges et al., 2010; OSullivan et al., 2016) , and innate immune hypothesis (Pais and Penha-Gonçalves, 2019). However, the exact mechanism remains elusive. There is evidence suggesting that the complement system plays a significant role in CM pathogenesis. In an early study using murine CM model with P. berghei ANKA (Finley et al., 1982) , T cell-deficient (nu/nu) mice were protected against CM compared to nu/+ mice, despite comparable parasitemia. The rapid decrease in serum C3 and concomitant increase in serum immune complexes observed in wildtype mice were absent in nu/nu mice, indicating the interaction between the complement system and cellular immunity in CM (Finley et al., 1982) . C1q and C5 protein levels were also significantly higher in the brain of CM mice compared to non-CM mice, suggesting the activation of the classical pathway (Lackner et al., 2008) . The roles for the complement system in CM were further examined using genetically modified mice, including mice deficient in C5 (Patel et al., 2008; Ramos et al., 2011; Buckingham et al., 2014) , C5aR (Ramos et al., 2011; Kim et al., 2014; McDonald et al., 2015) , C3 (Ramos et al., 2012) , C4 (Ramos et al., 2012) , FB (Ramos et al., 2012) , and C3aR (Ramos et al., 2011) . Notably, C5 deficient mice were fully protected from CM and CM-associated seizures (Ramos et al., 2011; Buckingham et al., 2014) , while C5aR deficient mice were only moderately protected (Ramos et al., 2011; Kim et al., 2014) . Mice lacking FB, C4, or C3aR showed outcomes comparable to wildtype mice (Ramos et al., 2011 (Ramos et al., , 2012 . In addition, C9 deposits were observed in the CNS during CM, and C9 inhibition (neutralizing anti-C9 antibody injection) significantly delayed CM development (Ramos et al., 2011) . Results from clinical studies also show complement activation during CM. Serum C5a levels were significantly higher in children with CM compared to those without CM (Kim et al., 2014) . Postmortem CM frontal lobes exhibited activation of complement, the coagulation cascade, and platelets (Kumar et al., 2018) . These data suggest that MAC formation plays a critical role in CM pathogenesis. In addition, persistent 

Plasmodium 1 (Human) Proteomic analysis on the frontal lobe (autopsy) of subjects with cerebral malaria (CM) caused by Plasmodium falciparum.

(1) Proteins associated with innate immune response, complement system (C1qb), coagulation, the platelet activation, are elevated in CM.

(2) Proteins associated with myelination, oxidative phosphorylation, ROS regulation, sodium and calcium ion transport are depleted in CM.

Innate immune responses (including the complement system) and associated demyelination may contribute to the severity of CM. Kumar et al., 2018 2 (in vivo) Experimental Malaria in Pregnancy (EMIP) model using P. berghei ANKA in mice (WT vs. C5aR deficient).

(1) In utero exposure to EMIP induced persistent neurocognitive deficit and affective disorders in the offspring.

(2) In utero EMIP-induced cognitive deficit in offspring was rescued by genetic or pharmacological disruption of C5aR signaling.

(3) In utero EMIP-induced reduction in neurotransmitter levels (dopamine, 5-HT, and norepinephrine) was observed only in WT (not in C5aR deficient) offspring.

In utero exposure to MIP induces cognitive deficit in offspring via maternal C5aR signaling. (1) C4 deficient and FB deficient mice were fully susceptible to CM.

(2) C3 deficient mice were partially resistant to CM. (1) C5 deficient mice were resistant to cerebral malaria, whereas C5aR deficient and C3aR deficient mice were susceptible.

(2) C9 deposition was detected throughout the cortex of infected mice. C9 deposits frequently colocalized with blood vessels, while some were detected in the parenchyma.

(3) anti-C9 antibody treatment significantly delayed the progress of cerebral malaria.

Protection of C5 deficient mice against cerebral malaria is mediated through the inhibition of MAC formation, not through C5a-induced inflammation. Ramos et al., 2011 7 (in vivo) CM model using P. berghei ANKA in mice of different genetic backgrounds. C5-deficient: A/J, C57BL/6 with C5-defective allele from A/J, and C5-deficient B10.D2. C5-sufficient: C57BL/6, A/J with C5-sufficient allele from C57BL/6, and C5-deficient B10.D2.

(1) CM was associated with the presence of C5 gene. C5-sufficient mice were susceptible while and C5-deficient mice were CM resistant.

(2) C5a and C5aR blockade rescued susceptible mice from CM. Increased C1q and C5 proteins in the brain of cerebral malaria. C1q and C5 levels correlated with clinical severity.

C1q and C5 are locally upregulated in the brain in cerebral malaria. Lackner et al., 2008 9 (in vivo) CM model using P. berghei ANKA in mice (BALB/c; nu/nu and nu/+) (in vivo)

(1) Compared to nu/+, nu/nu mice were protected against CM despite higher parasitemia.

(2) Early rapid decrease in serum C3 and increase in serum immune complex levels were observed in nu/+ mice, but not in nu/nu.

T cell-deficiency is protective against CM, which was accompanied by reduced complement activation. Finley et al., 1982 (Continued) Frontiers in Cellular Neuroscience | www.frontiersin.org (1) mRNA levels of C1qa, C3, FB, FP, C3aR, and C5aR were persistently up-regulated in the infected brain.

(2) C5a protein was up-regulated in the infected brain.

(3) Toxoplasma infection in glial cells induced the up-regulation of mRNA for C1qa, FB, FP, and C5aR in a microglia-dependent manner.

Toxoplasma infection induced the expression of the alternative pathway components (FB and FP) and anaphylatoxin receptors (C3aR and C5aR), which was partly mediated by microglia. Shinjyo et al., 2021 2 (in vivo) Chronic Toxoplasma infection model: Type II T. gondii (Prugniaud) in mice (Kumming). Measures: proteomics using brain tissue samples.

Complement (C3, C4b, and C1qa) and coagulation (e.g., plasminogen) pathways were highly upregulated in the brain of infected mice. Tight junction pathway was disordered.

In Toxoplasma-infected brain, complement components (C3, C4b, and C1q) were upregulated possibly causing the disruption of tight junctions. (1) Complement C1q, C1r, C3, and C4 levels were elevated in the brain with high Toxoplasma cyst burden.

(2) Complement proteins were deposited on the surface of degenerating neurons.

T. gondii cyst burden is associated with up-regulation of complement components (C1q, C1r, C3, and C4), which leads to complement deposition on the surface of degenerating neurons. (1) C1q mRNA and protein levels increased after infection.

C1q levels correlated with Toxoplasma cyst burden.

(2) C1q expression was predominantly cytoplasmic, which was in the cells adjacent to GFAP positive astrocytes, near breached cyst barriers.

(3) C1q colocalized with Toxoplasma cysts in the brain.

Toxoplasma infection causes upregulation of C1q in the brain, particularly near parasite cysts and punctate synaptic patterns.

The relevant complement proteins are highlighted in bold.

cognitive deficits caused in the offspring by in utero exposure to malaria were dependent on maternal C5a-C5aR signaling (McDonald et al., 2015) . These findings point to the role of C5a in the initiation of neuroinflammation together with the dysregulation of angiogenesis and synaptogenesis (McDonald et al., 2013) . Surprisingly, the formation of conventional C5 convertase via C3 activation was not required for CM progression (Ramos et al., 2012) , which suggests that C5 was activated by coagulation factors or other non-complement proteases (Ramos et al., 2012 ; Figure 2 ). These observations support the role for the complement system as a link between immune responses and dysregulated coagulation during CM. The interactions between Plasmodium and the complement system are possibly even more intricate (Schmidt et al., 2015; Kennedy et al., 2016 Kennedy et al., , 2017 Rosa et al., 2016) . Blood stage P. falciparum (free merozoites as well as intraerythrocytic schizonts) evades complement-mediated destruction by recruiting FH, a major negative regulator of complement activation, on the cell surface (Kennedy et al., 2016; Rosa et al., 2016) . As mentioned above, several other pathogens, including Neisseria meningitidis (Granoff et al., 2009; Schneider et al., 2009) and Borrelia burgdorferi (Kraiczy et al., 2001) , use FH for the same purpose, suggesting that it is an evolutionarily conserved strategy to circumvent complement-mediated elimination. Plasmodium utilizes another complement regulatory protein CR1 as a receptor for red blood cell invasion (Tham et al., 2010; Spadafora et al., 2010) . In addition, mobilization of CR1 on the surface of Plasmodium-infected red blood cells is required for rosetting (Rowe et al., 1997) , a process implicated in vascular obstruction during severe malaria (Carlson, 1993) . CR1 polymorphisms could explain the association between altered efficiency of rosetting and malaria severity (Cockburn et al., 2004; Schmidt et al., 2015) .

In conclusion, overactivation of complement cascade triggered by the parasite conceivably contributes to CM pathogenesis, and the inhibition of the complement cascade at the level or downstream of C5 activation, and/or the inhibition of CR1 could be a beneficial treatment strategy for CM.

Toxoplasma gondii infects approximately one-third of the world population. It is an opportunistic infection that in individuals with immunodeficiency can cause severe diseases, including Toxoplasma encephalitis (Marra, 2018) . Infection during pregnancy can lead to congenital toxoplasmosis, the severity of which depends on the stage of pregnancy (Bigna et al., 2020) . While Toxoplasma rarely causes symptoms in healthy individuals with effective immunity, it can establish latent infection in the brain and other tissues (Pittman and Knoll, 2015) . It is also notable that the virulence can vary depending on Toxoplasma genotype (Howe and Sibley, 1995; Behnke et al., 2011; Pomares et al., 2018; Taniguchi et al., 2018) . Once disseminated into the brain, the parasite transforms into bradyzoite form (cyst) and establishes a life-long infection in neurons and glia (Ólafsson and Barragan, 2020) . The presence of Toxoplasma cysts in the CNS has been linked to various FIGURE 2 | Known and potential interactions between complement proteins and infectious agents. Infectious agents can modulate the expression or activity of complement proteins and receptors in the brain parenchyma, CSF, and BBB. Highlighted are the core complement components/positive regulators (red) and negative regulators (RCAs) (blue), which are potentially affected by infectious agents. Infection-induced activation of the coagulation cascade can also lead to C3 and C5 cleavage via the extrinsic pathway. Pathogens known to interact with the respective complement proteins are presented in the boxes to the right or below the pathway diagram. B, bacteria; V, viruses; F, fungi; P, parasites; PrP, prion proteins.

neuropsychiatric disorders, such as schizophrenia (Elsheikha et al., 2016; Del Grande et al., 2017; Fuglewicz et al., 2017; Fond et al., 2018; Stepanova et al., 2019; Tyebji et al., 2019a,b) , possibly via the direct modulation of dopaminergic/serotonergic signaling as well as neuroinflammation (Henriquez et al., 2009; Mahmoud et al., 2017) . T cells and type II interferon (IFN-γ)dependent immune responses are an essential part of the host defense against Toxoplasma infection (Sasai et al., 2018) . Type I interferons (IFNs) also play an important regulatory role in the innate immune response during protozoan infection, including toxoplasmosis (Silva- Barrios and Stäger, 2017) .

Toxoplasma is classified into three groups: virulent type I, which causes acute infection, and avirulent type II and type III, which are responsible for chronic infection. Several studies have suggested the involvement of the complement system during acute Toxoplasma (type I) infection. Toxoplasma lytic activity of human sera was dependent on classical pathway components (C1q, C2, C4, C5, C6, C7, and C8) in a study using a virulent Toxoplasma strain in vitro (Schreiber and Feldman, 1980) . Animal sera (pig, rabbit, and dog), with the exception of cat serum, effectively killed Toxoplasma tachyzoites of a virulent strain via C1q and natural IgM-dependent complement activation (Kaneko et al., 2004) . Toxoplasma tachyzoites of the same strain were resistant to complement-mediated lysis via the formation of iC3b, the inactive form of C3b (Fuhrman and Joiner, 1989) . Toxoplasma tachyzoites of both virulent and avirulent strains mobilized complement regulatory proteins (FH and C4BP) on their surface to evade complement-mediated parasite killing in vitro, whereas C3 deficient mice suffered higher parasite burden in the brain and other organs in vivo, suggesting complex host-parasite interactions (Sikorski et al., 2020) . Of note, C5 deficiency rendered either protection or enhanced mortality depending on the genetic background of the murine host (Araujo et al., 1975) . These data suggest that, while the complement system plays a pivotal role in the protection against acute Toxoplasma infection, the parasite has evolved strategies to manipulate the complement system to survive and propagate in the host.

The interaction between Toxoplasma and the complement system in the brain has recently been elucidated. In murine Toxoplasma infection models, cerebral C1q is upregulated during chronic infection with virulent and avirulent strains , and persistent infection with a virulent Toxoplasma strain led to the upregulation of C1q, C1r, C3, and C4 mRNA levels and deposition of complement component proteins (C1q and C3) in the brain. These changes were associated with neurodegeneration ). An avirulent Toxoplasma strain also caused upregulation of complement proteins, including C3, C4b, and C1q, in the mouse brain (Huang et al., 2019) . Furthermore, mRNAs for FB and FP, C3aR, and C5aR were up-regulated in the brain of mice chronically infected with an avirulent Toxoplasma strain (Shinjyo et al., 2021) , suggesting that the alternative pathway is activated in the brain during chronic infection. The Toxoplasma infection-induced up-regulation of FB, FP, and C5aR mRNAs occurred in primary murine glial cells in vitro in a microglia-dependent manner (Shinjyo et al., 2021) . These data suggest that, while complement-dependent clearance is essential in the initial, peripheral phase of infection, chronic Toxoplasma infection can cause persistent complement activation in the CNS.

Transmissible spongiform encephalopathies (TSEs, prion diseases) are fatal neurodegenerative diseases, which include bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and goat, Creutzfeldt-Jakob disease (CJD), fatal familial insomnia, and Gerstmann-Sträussler-Scheinker syndrome in humans Prusiner, 1998) . Most neurodegenerative diseases, including prion diseases and AD, share two common features: the accumulation and selfpropagation of misfolded proteins (Gomez-Gutierrez and Morales, 2020). TSE-causing infectious prion proteins (PrP Sc ) transmit the disease-associated conformation to normal prion proteins (PrP C ), leading to further propagation of PrP Sc . Following peripheral exposure and prior to neuroinvasion, PrP Sc accumulates in lymphoid tissues, including lymph nodes and Peyer's patches. Early PrP Sc accumulation occurs within the germinal center on follicular dendritic cells (FDCs) (Brown et al., 1999) as well as within tingible body macrophages (McGovern and Jeffrey, 2007) . From the lymphoid tissues, transmission to the CNS occurs via the peripheral nervous system (Glatzel et al., 2001) . The central event in prion disease progression is the accumulation of PrP Sc in the CNS accompanied by neuronal loss and spongiform neuropils, suggesting aggressive destruction of neural networks (Budka, 2000) .

The involvement of the complement system in prion-induced neuropathology has been observed in different types of prion diseases (Bonifati and Kishore, 2007;  Table 1 .5). In scrapieinfected rodents, total complement activity in the brain was significantly increased at the terminal stage (Lv et al., 2014) . In addition, C1q upregulation (Dandoy-Dron et al., 1998 , 2000 Carroll et al., 2018) , C3 upregulation and colocalization with neurons, and MAC deposition on neurons were observed in infected human brain (Kovacs et al., 2004) as well as in scrapie model in mice (Lv et al., 2014) , suggesting the activation of the classical and terminal pathways. C1q also colocalized with infected neurons in vitro, and throughout the brain C1q distribution overlapped with PrP (Hasebe et al., 2012) . In addition, FB and FP levels significantly increased in the brain of scrapie-infected mice, while FB and C3 colocalized with neurons and activated microglia (Chen et al., 2020) , suggesting the activation of the alternative pathway and microglia. Notably, mice deficient in C1q or FB/C2 were protected against encephalopathy after intraperitoneal prion exposure, but C3 deficiency was not protective (Klein et al., 2001) . Interestingly, reactive astrocytes in prion diseases are characterized by C3 up-regulation and mixed A1/A2 phenotype (Hartmann et al., 2019) distinct from neurotoxic astrocytes observed in other neurodegenerative diseases (Kwon and Koh, 2020) . The abolishment of C3-positive astrocytes led to prion disease acceleration (Hartmann et al., 2019) . These data suggest that C3 plays multiple roles in prion disease progression, depending on the context. In contrast, complement hemolytic activity was significantly lower in the CSF of CJD patients, particularly in genetic CJD cases (Chen et al., 2016) . In addition, the protein levels of some complement components, including C3, C4, and C9, decreased in the CSF of sporadic CJD (sCJD) patients compared to non-CJD group (Chen et al., 2016) . While the explanation conceivably lies in the increased consumption of complement in the brain parenchyma, the neuropathologic implications of these findings are currently elusive.

Given that FH deficiency was protective against PrP propagation (Kane et al., 2017) , prion proteins may escape complement-mediated clearance by manipulating FH-dependent complement inhibition, possibly via direct interaction between PrP Sc and FH (Kane et al., 2017) . Thus, RCAs seem important target molecules exploited by infectious agents, including prion proteins, to evade innate immunity and propagate throughout the body including the CNS.

The consequences of local complement activation by infectious agents for brain tissue integrity and function are highly context dependent. Complement has a role in the regulation of normal neuronal functioning and homeostasis. It may be neuroprotective and play a critical role in the elimination of various pathogens, but can also be a major mediator of neurodegeneration and tissue damage. The complement system can also be hijacked by some pathogens and play a complicit role in their dissemination. Figure 2 illustrates the potential interactions between the complement system and infectious agents, and Table 2 summarizes the responses of selected complement proteins to the individual pathogens, including up-or down-regulation, deposition, and the impact of genetic polymorphism or genetic manipulations.

In the CNS, C1q plays potentially harmful roles in bacterial (S. pneumoniae-induced bacterial meningitis) (Zwijnenburg et al., 2007) , viral (HIV-associated cognitive impairment) (McGuire et al., 2016) , parasite (Plasmodium, CM) (Lackner et al., 2008) , and prion (Klein et al., 2001) infections, while it may be protective during the initial phase of prion disease (Flores-Langarica et al., 2009) . Jointly these findings indicate the deleterious consequences of overactivation of the classical pathway. The lectin pathway is protective against herpes simplex virus encephalitis by inhibiting viral dissemination into the CNS (Bibert et al., 2019) . While C3-mediated pathogen clearance is beneficial in the periphery (Mehlhop et al., 2005; Brooke et al., 2012; Sun et al., 2016) , C3d deposition on synaptic terminals may facilitate synaptic loss in WNV infection (Vasek et al., 2016) . Likewise, the net outcome of downstream complement activation seems to be context-dependent. C5 is important for fungal clearance in the vasculature and inhibits fungal dissemination into the CNS (Tuite et al., 2005) . In contrast, in the Plasmodium infection, C5 deficiency is protective against CM (Patel et al., 2008; Ramos et al., 2011; Buckingham et al., 2014) . Inhibition of MAC formation was also protective against (1) FB and FP (properdin) levels significantly increased in the brain of scrapie-infected mice.

(2) FB and C3 colocalization was observed with neurons and activated microglia, but not with astrocytes.

The alternative pathway is activated and plays a role in triggering the complement cascade in the brain during prion infection-induced neuropathogenesis.

Chen et al., 2020 2 Human sCJD and scrapie

(1) (Human) Postmortem sCJD brain specimens (2) (in vivo) Prion disease model in mice (WT vs. Triple deficient lacking TNF-α, IL-1α and C1qa)

(1) C3 + -astrocytes (A1-like-astrocytes) were abundant in mouse and human prion diseases.

(2) Mice lacking TNF-α, IL-1α and C1qa had accelerated prion disease course (measured by survival rate) without affecting the formation of PrP Sc and microglial activation.

(3) C3 expression was significantly up-regulated and C3 + -astrocytes significantly increased in the thalamus of terminally sick WT but not in Triple deficient mice.

Reactive astrocyte signature in prion diseases is characterized by upregulation of C3 and a mixed A1/A2 phenotype, which is distinct from other neurodegenerative diseases. C3 expression in astrocytes may be protective in prion disease. (1) RNA levels of complement components (C4b, C1qa, C1qb, and C1qc), DAMP receptors (i.e., Tlr2, Tlr4, Tlr8, C3ar1 and C5ar1) were upregulated in the thalamus and the whole brain.

(2) TLR2 deficient, but not C3aR deficient and C5aR deficient, caused higher susceptibility to prion disease.

(3) TLR2 deficient or C5aR deficient did not alter the transcription of proinflammatory genes. (1) Brain PrP loads correlated with Cfh expression.

(2) Splenic propagation and clinical manifestation were delayed by FH deficiency.

(3) FH directly interacts with PrP Sc .

(a) FH enhances scrapie-induced brain prion load.

(b) FH directly binds prions. Kane et al., 2017 5 Human sCJD (Human) CSF from prion disease patients and non-prion disease patients.

(1) Complement hemolytic activity (CH50) was lower in the CSF from sCJD patients. CH50 was consistently lower in genetic prion disease patients.

(2) C3, C4, and C9 protein levels were lower in the CSF from sCJD patients.

Complement activity is down-regulated in the CSF of CJD patients, conceivably through consumption. Chen et al., 2016 6 Scrapie (prion disease) (in vivo) Prion disease model (scrapie) in mice and hamster: 139A-infected mice and 263K-infected hamster

(1) Total complement activity (CH50) was higher in the brain of scrapie-infected rodents.

(2) C1q was upregulated in the brain of scrapie-infected rodents.

(3) Stronger C3 signals in scrapie-infected brain. C3 colocalized with astrocytes, microglia, and neurons.

(4) MAC was deposited in the infected brain and colocalized with neurons.

The activation of the complement system may be a hallmark during prion infection. Lv et al., 2014 7 Scrapie (prion disease) (in vivo and in vitro) Scrapie (Chandler and 22L) infection model: mice and N2a cells.

(1) C1q colocalized with PrP in Chandler-infected N2a cells, while C3 colocalized with PrP in 22L-infected N2a cells.

(2) C1q colocalized with PrP throughout the brain and mild C3 deposition was detected in the cerebral cortex, septum, thalamus, midbrain, and pons in Chandler-infected brain. C1q was absent in the dorsal part of thalamus and C3 was more pronounced in the thalamus compared to Chandler-infected brain.

Prion-induced complement activation is PrP strain dependent.

The relevant complement proteins are highlighted in bold.

Frontiers in Cellular Neuroscience | www.frontiersin.org The relevant complement proteins are highlighted in bold.

CM (Ramos et al., 2011) , confirming the crucial role of terminal complement pathway in CM pathogenesis. C3aR was up-regulated in the brain upon viral infection (Libbey et al., 2017) and C3aR deficiency was protective against viral infectioninduced synaptic loss (Vasek et al., 2016) . C5aR deficiency was also protective against CM development (Patel et al., 2008; Kim et al., 2014; McDonald et al., 2015) , as well as bacterial meningitis (Woehrl et al., 2011) . However, neither C3aR deficiency nor C5aR deficiency were protective against prion-induced neuropathology (Carroll et al., 2018) , indicating pathogen-specific roles of anaphylatoxin receptors in the CNS. CD46, a negative regulator of the classical and lectin pathways, aids in the dissemination of bacteria (N. meningitidis) (Johansson et al., 2003 (Johansson et al., , 2005 and viruses [Measles virus (Rall et al., 1997; Manchester et al., 1999; Oldstone et al., 1999; Evlashev et al., 2000) and HHV-6 (Cassiani-Ingoni et al., 2005) ] into the CNS, leading to meningitis and encephalitis, respectively. While the use of CD46 by these pathogens could be an evasion strategy FIGURE 3 | Infection-induced complement activation in the CNS and potential links to neurodegeneration and dementia. (A) The most simplified view of how CNS infection can lead to neurodegeneration and dementia is enclosed in the dotted rectangle. Infection-induced complement activation products may contribute to neurodegeneration and dementia via interaction with amyloid deposits and enhanced neuroinflammation. (B) A more detailed schematic representation of specific interactions between infectious agents and the complement system as a potential mechanistic link between CNS infection, neurodegeneration and dementia. The consequences of complement activation may be context-dependent. For example, MAC plays a role in pathogen elimination but can also contribute to tissue damage. C3a and C5a can support tissue repair and adaptive neural plasticity, but also promote potentially detrimental inflammation and leukocyte recruitment. Opsonization and phagocytosis are needed for clearance of pathogens, but the same mechanisms are involved in synapse elimination as the first step in neurodegeneration.

from the classical or lectin pathway-mediated clearance, CD46dependent facilitation of immune cell infiltration into the CNS (Manchester et al., 1999; Oldstone et al., 1999) and cell-cell fusion of infected lymphocytes and glial cells (Cassiani-Ingoni et al., 2005) suggest higher mechanistic complexity of the interactions between complement and infectious agents. FH, a negative regulator of the alternative pathway, is also engaged in the dissemination of pathogens in bacterial (S. suis) (Kong et al., 2017) and prion infections (Kane et al., 2017) , indicating that these infectious agents manipulate the alternative complement pathway for their propagation in the brain. The fact that a viral RCA homolog plays a facilitatory role in viral dissemination via the inhibition of C3-dependent host defense (Kapadia et al., 2002) suggests that infectious agents have evolved diverse molecular mechanisms to escape complement-mediated killing.

Considering the link between cognitive impairment and aberrant complement activation in the CNS (Aiyaz et al., 2012; Rubio-Perez and Morillas-Ruiz, 2012) , the most simplified view is that CNS infection could lead to dementia via the complement activation ( Figure 3A : dotted rectangle). However, as discussed above, the mechanistic links between infectious agents, complement, and neurodegeneration are far more complex. Due to the multiple neurodevelopmental and homeostatic functions that the complement system and its individual components play in the brain (Figure 1) , complement activation by infectious agents can cause an imbalance in the intricate web of interactions between complement proteins and the nervous system with deleterious consequences for CNS tissue integrity and function ( Figure 3B : solid rectangle). This could explain the unpredictable and sometimes inconsistent observations in different studies in human patients as well as in animal models of CNS infection. The multiple functions of the complement system in the CNS together with the complexity of immune responses to infection call for well-informed and highly selective approaches when manipulating the complement system for therapeutic benefit. For example, inhibiting the downstream of complement cascade (C5 and MAC) and/or C5aR could protect the brain from Plasmodium infection-induced tissue damage (Patel et al., 2008; Ramos et al., 2011; Buckingham et al., 2014; Kim et al., 2014) , whereas inhibition restricted to the upstream components (C1q, C2, and FB) could be beneficial in prion diseases (Klein et al., 2001) , as shown in animal models. However, these studies were conducted using constitutive inactivation of specific genes. As the complement system plays multiple roles in the CNS, roles which are distinct from those in the periphery, it is imperative to investigate CNS-specific roles of the complement system in the context of an infection by a specific pathogen. Furthermore, while complement proteins are locally produced in the brain, it is less clear which cell types are responsible, how complement protein production and responses are regulated, and how are these processes influenced by various stimuli under physiological and pathological conditions, including CNS infection. Of particular interest in this respect are the potential functions of intracellular C3 (Elvington et al., 2016) , not only with regard to the interactions between infectious agents and the brain-resident cells but also the role of intracellular C3 in neurodegeneration. Considering the diverse roles of glial cells (astrocytes and microglia, the brain-resident macrophages) in the maintenance of CNS homeostasis, further studies are required to elucidate how infectious agents modulate complement generation in glial cells and how, in turn, it might affect the phenotypes of these cells.

Of the approximately 50 million people with dementia worldwide, about 50% live in low-and middle-income countries (WHO, 2019). Considering higher risk of infection and infection-induced brain disorders in those countries (Fernandes and Caramelli, 2019; Singh et al., 2020) , understanding of the potential mechanistic links between infection and neurodegenerative disorders including dementia, will inform the development of preventive and therapeutic strategies. While amyloidogenesis is widely accepted as the underlying cause of AD and other forms of neurodegenerative diseases, Aβ-targeting drug development has been so far unsuccessful (Robakis, 2020) . Given that the presence of amyloid plaques does not necessarily indicate cognitive decline (Skaper, 2012; Robakis, 2020) , alternative culprits and theories are needed. Indeed, there is a growing body of evidence showing that innate immunity and neuroinflammation play a pivotal role in dementia development (Leng and Edison, 2020) .

Separated from the other parts of the body by the BBB and CSF barrier, the CNS is uniquely protected by special immune components, including the complement system and glial cells. While locally produced complement components play crucial homeostatic roles in the CNS, dysregulated complement activity could be detrimental to the function of the CNS. As the key element of brain-resident innate immunity, the complement system plays both protective and destructive roles in neurodegeneration (Kolev et al., 2009) . Whereas aberrant complement activation is frequently associated with neuroinflammation and neurodegenerative disorders, the complement system exerts homeostatic functions via eliminating apoptotic cells, cell debris, and toxic substances, and supports plasticity and tissue repair. A broad range of infectious agents can potentially interact with the complement system in the brain and the net outcome of these interactions appears to depend on the specific pathogens, the target components, and the mode of interaction. It is therefore conceivable that pathogen-triggered and persistent activation of the complement system represents the missing mechanistic link between infection, in particular infection affecting the CNS, and neurodegeneration. We are fully aware that the simplified view presented in Figure 3 does not capture every aspect of the involvement of the complement system in infection-induced neuropathology and neurodegeneration, but only highlights the key components of the interplay between pathogens and complement activation induced-neurodegenerative processes that may lead to dementia. While the specific mechanistic links between CNS infection, neurodegeneration and dementia are still unclear, the involvement of the complement system and the pathogen-and disease stage-specific roles of the individual complement proteins warrant further intense investigation.

NS wrote the first draft of the manuscript. MP and WK critically assessed the content. NS and MP jointly revised and finalized the manuscript. All the authors contributed to the article and approved the submitted version.

Complement activation as a biomarker for Alzheimer's disease

Fungal infection in patients with Alzheimer's disease

Infection of fungi and bacteria in brain tissue from elderly persons and patients with Alzheimer's disease. Front

Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patients

Molecular interacommunication between the complement and coagulation systems

Kaposi's sarcoma-associated herpesvirus-related solid lymphoma involving the heart and brain

Experimental Toxoplasma gondii infection in mice: the role of the fifth component of complement

Systemic distribution of West Nile virus infection: postmortem immunohistochemical study of six cases

Brain macrophages in simian immunodeficiency virus-infected, antiretroviralsuppressed macaques: a functional latent reservoir

Brain localization of Kaposi's sarcoma in a patient treated by combination antiretroviral therapy

Expression of the complement C3a and C5a receptors after permanent focal ischemia: an alternative interpretation

Virulence differences in Toxoplasma mediated by amplification of a family of polymorphic pseudokinases

Staphylococcus epidermidis bacteremia induces brain injury in neonatal mice via toll-like receptor 2-dependent and -independent pathways

Herpes simplex encephalitis in adult patients with MASP-2 deficiency

Global, regional, and country seroprevalence of Toxoplasma gondii in pregnant women: a systematic review, modelling and meta-analysis

Role of complement in neurodegeneration and neuroinflammation

Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma

Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2

Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings

Guillain-Barré syndrome, acute disseminated encephalomyelitis and encephalitis associated with zika virus infection in Brazil: detection of viral RNA and isolation of virus during late infection

Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus infection

Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis

Scrapie replication in lymphoid tissues depends on prion proteinexpressing follicular dendritic cells

Complement C5-deficient Mice are protected from seizures in experimental cerebral malaria

Histopathology and immunohistochemistry of human transmissible spongiform encephalopathies (TSEs)

Beta-amyloid peptides initiate the complement cascade without producing a comparable effect on the terminal pathway in vitro

Herpes virus in Alzheimer's disease: relation to progression of the disease

Erythrocyte rosetting in Plasmodium falciparum malaria-with special reference to the pathogenesis of cerebral malaria. Scand

Toll-like receptor 2 confers partial neuroprotection during prion disease

CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion

Induction of proinflammatory multiple sclerosisassociated retrovirus envelope protein by human herpesvirus-6A and CD46 receptor engagement

Alternative complement pathway is activated in the brains of scrapie-infected rodents

Low activity of complement in the cerebrospinal fluid of the patients with various prion diseases

Death receptor-mediated apoptotic signaling is activated in the brain following infection with West Nile virus in the absence of a peripheral immune response

HIV-associated neurocognitive disorder

A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria

Complement C3a receptor modulates embryonic neural progenitor cell proliferation and cognitive performance

Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth

Microglial complement receptor 3 regulates brain Abeta levels through secreted proteolytic activity

Enhanced levels of scrapie responsive gene mRNA in BSEinfected mouse brain

Cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts

Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease

Is Toxoplasma gondii a trigger of bipolar disorder? Pathogens

C3d of complement as a molecular adjuvant: bridging innate and acquired immunity

Increase of C1q biosynthesis in brain microglia and macrophages during lentivirus infection in the rhesus macaque is sensitive to antiretroviral treatment with 6-chloro-2 ,3 -dideoxyguanosine

Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis

Streptococcus suis serotype 2, an important swine and human pathogen, induces strong systemic and cerebral inflammatory responses in a mouse model of infection

Cytokines and chemokines in cerebral malaria pathogenesis

Neuroinflammation in Alzheimer's disease and prion disease

Complement activation in amyloid plaques in Alzheimer's dementia

The known and missing links between Toxoplasma gondii and schizophrenia

Evolution of the complement system: from defense of the single cell to guardian of the intravascular space

Productive measles virus brain infection and apoptosis in CD46 transgenic mice

Evolution of the complement system

Ischemic stroke and infectious diseases in low-income and middle-income countries

Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice

Properdin deficiency: molecular basis and disease association

Virulent P. berghei malaria: prolonged survival and decreased cerebral pathology in cell-dependent nude mice

Scrapie pathogenesis: the role of complement C1q in scrapie agent uptake by conventional dendritic cells

The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity

Latent Toxoplasma infection in real-world schizophrenia: results from the national FACE-SZ cohort

Does activation of the blood coagulation cascade have a role in malaria pathogenesis?

Fatal cerebral malaria: a venous efflux problem

Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia

Relationship between toxoplasmosis and schizophrenia: a review

Toxoplasma gondii: mechanism of resistance to complement-mediated killing

Therapeutic targeting of the complement system: from rare diseases to pandemics

Complement components of the innate immune system in health and disease in the CNS

The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis

Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion

The prion-like phenomenon in Alzheimer's disease: evidence of pathology transmission in humans

Neuroinfections caused by fungi

Developmental activities of the complement pathway in migrating neurons

Fungal meningitis

Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera

Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria

Granulocyte colony stimulating factor therapy of experimental cryptococcal meningitis

Measles virus persistence and its consequences

HIV Tat causes synapse loss in a mouse model of HIV-associated neurocognitive disorder that is independent of the classical complement cascade component C1q

Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand

Complement 3(+)-astrocytes are highly abundant in prion diseases, but their abolishment led to an accelerated disease course and early dysregulation of microglia

Reaction of complement factors varies with prion strains in vitro and in vivo

Neuropsychiatric disease and Toxoplasma gondii infection

HSV-1 infection of human brain cells induces miRNA-146a and Alzheimertype inflammatory signaling

Complement and microglia mediate early synapse loss in Alzheimer mouse models

Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease

A double-edged sword: complement component 3 in Toxoplasma gondii infection

Europe PMC funders group cerebral malaria?; mechanisms of brain injury and strategies for improved neuro-cognitive outcome

Expression of a functional anaphylatoxin C3a receptor by astrocytes

Corroboration of a Major role for herpes simplex virus type 1 in Alzheimer's disease. Front

Innate lymphoid cells in protection, pathology, and adaptive immunity during apicomplexan infection

CD46 in meningococcal disease

Human-like immune responses in CD46 transgenic mice

Effects of granulocyte neutral proteases on complement components

Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease

Complement regulatory protein factor H Is a soluble prion receptor that potentiates peripheral prion pathogenesis

Natural IgM antibodies in sera from various animals but not the cat kill Toxoplasma gondii by activating the classical complement pathway

Critical role of complement and viral evasion of complement in acute, persistent, and latent gamma-herpesvirus infection

Murine gammaherpesvirus 68 encodes a functional regulator of complement activation

Recruitment of factor H as a novel complement evasion strategy for blood-stage Plasmodium falciparum infection

Recruitment of human C1 esterase inhibitor controls complement activation on blood stage Plasmodium falciparum merozoites

Functional roles for C5a and C5aR but Not C5L2 in the pathogenesis of human and experimental cerebral malaria

Intracellular cytosolic complement component C3 regulates cytoprotective autophagy in pancreatic beta cells by interaction with ATG16L1

Complement facilitates early prion pathogenesis

Targeting the complement system in bacterial meningitis

Implication of complement system and its regulators in Alzheimer's disease

Interaction of factor H-binding protein of Streptococcus suis with globotriaosylceramide promotes the development of meningitis

Complement activation in human prion disease

Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and Factor H

Intracellular C3 protects human airway epithelial cells from stressassociated cell death

Identification of host-response in cerebral malaria patients using quantitative proteomic analysis

Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes

Complement factors C1q, C3 and C5 in brain and serum of mice with cerebral malaria

Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis

Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Persistent Toxoplasma infection of the brain induced neurodegeneration associated with activation of complement and microglia

Complement components are expressed by infiltrating macrophages/activated microglia early following viral infection

Organ-specific innate immune responses in a mouse model of invasive candidiasis

Complement's hidden arsenal: New insights and novel functions inside the cell

Control of the complement system

Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation

Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46)

Complement and HIV-I infection/HIV-associated neurocognitive disorders

Role for C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans

Remarkable activation of the complement system and aberrant neuronal localization of the membrane attack complex in the brain tissues of scrapie-infected rodents

Complement regulatory protein CD46 protects against choroidal neovascularization in mice

Involvement of host defense mechanisms against Toxoplasma gondii infection in anhedonic and despair-like behaviors in mice

Characterization of the inflammatory response during acute measles encephalitis in NSE-CD46 transgenic mice

The role of complement in inflammatory diseases from behind the scenes into the spotlight

Central nervous system infection with Toxoplasma gondii

Molecules great and small: the complement system

Complement activation in capillary cerebral amyloid angiopathy

Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation

Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: a narrative review for clinicians

Virus-induced immunosuppression: infections with measles virus and human immunodeficiency virus

Experimental malaria in pregnancy induces neurocognitive injury in uninfected offspring via a C5a-C5a receptor dependent pathway

The impact of placental malaria on neurodevelopment of exposed infants: a role for the complement system?

Scrapie-specific pathology of sheep lymphoid tissues

The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth

An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis

Acute myelitis due to Zika virus infection

Complement activation is required for induction of a protective antibody response against West Nile virus infection

Pathogenesis and pathophysiology of pneumococcal meningitis

The role of complement in neurological and neuropsychiatric diseases

Complement in the pathogenesis of Alzheimer's disease

Rapid Proteome changes in plasma and cerebrospinal fluid following bacterial infection in preterm newborn pigs

Complement anaphylatoxin receptors on neurons: new tricks for old receptors?

Neuronal integrity and complement control synaptic material clearance by microglia after CNS injury

Absence of measles virus receptor (CD46) in lesions of subacute sclerosing panencephalitis brains

The unicellular eukaryotic parasite Toxoplasma gondii hijacks the migration machinery of mononuclear phagocytes to promote its dissemination

Measles virus infection in a transgenic model: virus-induced immunosuppression and central nervous system disease

Risk factors and pathogenesis of HIV-associated neurocognitive disorder: the role of host genetics

Emerging roles for hemostatic dysfunction in malaria pathogenesis

Brain endothelium: the "innate immunity response hypothesis" in cerebral malaria pathogenesis

Fungal infections of the central nervous system

Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans

C5 deficiency and C5a or C5aR blockade protects against cerebral malaria

Altered cognitive performance and synaptic function in the hippocampus of mice lacking C3

Molecular immunobiology of complement biosynthesis: a model of single-cell control of effector-inhibitor balance

Fhb, a novel factor H-binding surface protein, contributes to the antiphagocytic ability and virulence of Streptococcus suis

Long-Term relationships: the complicated interplay between the host and the developmental stages of Toxoplasma gondii during acute and chronic infections. Microbiol

Genetic characterization of Toxoplasma gondii DNA samples isolated from humans living in North America: an unexpected high prevalence of atypical genotypes

Hyperactive behavior and altered brain morphology in adult complement C3a receptor deficient mice

Prion protein biology

Complement: a novel factor in basal and ischemiainduced neurogenesis

Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis

A transgenic mouse model for measles virus infection of the brain

Complement induction and complement evasion in patients with cerebral aspergillosis

Cutting edge: the membrane attack complex of complement is required for the development of murine experimental cerebral malaria

The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria

Zika virus and birth defects-reviewing the evidence for causality

Multiscale analysis of independent Alzheimer's cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus

Desperately seeking therapies for cerebral malaria

What do recent clinical trials teach us about the etiology of AD

Complement activation by beta-amyloid in Alzheimer disease

The Plasmodium falciparum blood stages acquire factor H family proteins to evade destruction by human complemen

Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency

Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease

P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1

A review: inflammatory process in Alzheimer's disease, role of cytokines

CNS aspergillosis: recognition, diagnosis and management

Zika infection and the development of neurological defects

Nucleotide sequence of the Kaposi sarcoma

Persistent neuropsychological impairment associated with West Nile virus infection

Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8 encephalitis in HIV-positive andnegative individuals

Host immune responses to Toxoplasma gondii

Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias

Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner

The good, the bad, and the opportunities of the complement system in neurodegenerative disease

More than just immune evasion: hijacking complement by Plasmodium falciparum

Cerebral malaria in Tanzania. Its epidemiology, clinical symptoms and neurological long term sequelae in the light of 66 cases

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

Identification of the activator system for antibody to Toxoplasma as the classical complement pathway

Neurologic manifestations and outcome of West Nile virus infection

Schizophrenia risk from complex variation of complement component 4

Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

Complement C3 deficiency protects against neurodegeneration in aged plaquerich APP/PS1 mice

Complement C3-deficient mice fail to display age-related hippocampal decline

Toxoplasma infection induces sustained up-regulation of complement factor B and C5a receptor in the mouse brain via microglial activation: implication for the alternative complement pathway activation and anaphylatoxin signaling in cerebral toxoplasmosis

Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells in vitro

Toxoplasma gondii recruits factor H and C4b-Binding protein to mediate resistance to serum killing and promote parasite persistence in vivo

A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain

Protozoan parasites and type I IFNs

Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries

Alzheimer's disease and amyloid: culprit or coincidence?

Late neurological consequences of Zika Virus infection: risk factors and pharmaceutical approaches

Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum

Neuroinvasion by pathogens: a key role of the complement system

Complement synthesis and activation in the brain of SIV-infected monkeys

Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections

Evidence for intrathecal synthesis of alternative pathway complement activation proteins in experimental meningitis

Toxoplasmosis and mental disorders in the Russian Federation (with special reference to schizophrenia)

The classical complement cascade mediates CNS synapse elimination

Complement peptide C3a stimulates neural plasticity after experimental brain ischemia

Complement C3a: shaping the plasticity of the post-stroke brain

Multiple sclerosis: in situ evidence for antibody-and complement-mediated demyelination

Cognitive and behavioral manifestations in SARS-CoV-2 infection: not specific or distinctive features?

Intravascular clearance of disseminating Cryptococcus neoformans in the brain can be improved by enhancing neutrophil recruitment in mice

Atypical virulence in a type III Toxoplasma gondii strain isolated in Japan

Complement-mediated events in Alzheimer's disease: mechanisms and potential therapeutic targets

New tricks for an ancient system: physiological and pathological roles of complement in the CNS

Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand

Kaposi's sarcoma-associated herpesvirus infection of neurons in HIV-positive patients

Genetic control of susceptibility to Candida albicans in susceptible A/J and resistant C57BL/6J mice

Impaired social behaviour and molecular mediators of associated neural circuits during chronic Toxoplasma gondii infection in female mice

Toxoplasmosis: a pathway to neuropsychiatric disorder

Community-acquired bacterial meningitis

Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series

A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction

A complement-microglial axis drives synapse loss during virus-induced memory impairment

Complement in the brain

Association of TRAF1/C5 locus polymorphisms with epilepsy and clinical traits in mexican patients with neurocysticercosis

Complete sequence and genomic analysis of murine gammaherpesvirus 68

TGF-beta1 released from activated platelets can induce TNF-stimulated human brain endothelium apoptosis: a new mechanism for microvascular lesion during cerebral malaria

Severe malaria: what's new on the pathogenesis front?

Transmission cycles, host range, evolution and emergence of arboviral disease

Venezuelan equine encephalitis

Dementia Fact sheet

Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis

The role of the complement system and the activation fragment C5a in the central nervous system

Differential effects of Tat proteins derived from HIV-1 subtypes B and recombinant CRF02_AG on human brain microvascular endothelial cells: implications for blood-brain barrier dysfunction

The C3a/C3aR axis mediates anti-inflammatory activity and protects against uropathogenic E coli-induced kidney injury in mice

The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization

Prominent neurodegeneration and increased plaque formation in complementinhibited Alzheimer's mice

Cerebral complement C1q activation in chronic Toxoplasma infection

Complement in neuroprotection and neurodegeneration

Activation of C3a receptor is required in cigarette smoke-mediated emphysema

Cerebral malaria: insight into pathogenesis, complications and molecular biomarkers

Microglial CR3 activation triggers long-term synaptic depression in the hippocampus via NADPH oxidase

C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice

FUNDING MP's research was supported by the Swedish Research Council (2017-00991), Hjärnfonden/The Swedish Brain Foundation, the Swedish state under the agreement between the Swedish Government and the county councils, the ALF agreement (716591), E. Jacobson's Foundation, and R. and U. Amlöv's Foundation. NS's research was supported by JSPS KAKENHI Grant No. 19K07839. 

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.